TransCode Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	5	3	9	33	-	-
Market Cap Growth	-47.72%	-62.08%	-73.35%	-	-	-
Enterprise Value	1	1	4	12	1	1
PE Ratio	-	-0.18	-0.50	-4.79	-	-
PB Ratio	1.20	2.02	2.70	1.61	-	-
P/FCF Ratio	-0.16	-0.18	-0.55	-5.94	-	-
P/OCF Ratio	-0.16	-0.18	-0.55	-6.22	-	-
EV/EBITDA Ratio	0.11	-0.06	-0.22	-1.78	-0.65	-1.61
EV/EBIT Ratio	0.10	-0.05	-0.21	-1.77	-0.65	-1.61
EV/FCF Ratio	0.10	-0.05	-0.24	-2.17	-2.55	-1.42
Debt / Equity Ratio	0.07	0.27	-	-	-0.61	-0.84
Debt / EBITDA Ratio	-0.02	-0.03	-	-	-1.07	-2.06
Debt / FCF Ratio	-0.02	-0.02	-	-	-4.23	-1.82
Quick Ratio	1.82	0.79	1.23	8.22	2.05	3.25
Current Ratio	2.48	1.28	1.70	8.97	2.05	3.25
Interest Coverage	-258.98	-330.78	-548.15	-70.98	-4.94	-2.87
Return on Equity (ROE)	-534.80%	-934.70%	-171.70%	-89.20%	103.80%	-
Return on Assets (ROA)	-238.80%	-276.10%	-133.60%	-53.80%	-372.10%	-
Return on Capital (ROIC)	-361.65%	-928.50%	-574.99%	-30.15%	54.98%	251.06%
Earnings Yield	-310.69%	-559.95%	-201.12%	-20.88%	-	-
FCF Yield	-319.23%	-546.79%	-181.64%	-16.84%	-	-
Buyback Yield / Dilution	-27557.71%	-1003.48%	-54.03%	-81.74%	-	-
Total Shareholder Return	-27557.71%	-1003.48%	-54.03%	-81.74%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).